PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.
Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Ludwigstrasse 4, Fürstenfeldbruck,d-82256,germany
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- http://www.prime-study.eu
- Keywords
- research, insulin, Alzheimer's disease, type 2 diabetes, metabolic syndrome, obesity, obsessive compulsive disorder, autism spectrum disorders, genetics, animal models, dissemination, epidemiology, clinical guidelines.
- HQ
- Fürstenfeldbruck
Prime Horizon2020 Questions
Prime Horizon2020's website is http://www.prime-study.eu
Prime Horizon2020's LinkedIn profile is https://de.linkedin.com/company/prime-horizon2020
Prime Horizon2020 has
1 employees.
View email and phone details for 1
employees at Prime Horizon2020.
Prime Horizon2020's industry is
Research Services
Prime Horizon2020's categories are Research Services
Prime Horizon2020's founding year is 2020
